Patent claims

1. A corticoid 17,21-dicarboxylic ester or corticoid 17-carboxylic ester 21-carbonic ester of the formula I



I

in which:

A is CHOH and CHCl in arbitrary steric arrangement, CH_2, C=O or 9(11) double bond,

Y is hydrogen, fluorine or chlorine,

Z is hydrogen, fluorine or methyl,

R(1) is optionally substituted or fused aryl or hetaryl

(C_1-C_4)-alkyl is saturated, unsaturated once or more than once, branched by further alkyl groups, unsubstituted or inserted or substituted by heteroatoms O, S or N,

n is zero or 1,

m is zero or 1,

R(2) is linear or branched (C_1-C_8)-alkyl,

 or $-CH_2-$.

R(3) is hydrogen or α- or β-methyl.

2. A corticoid 17,21-dicarboxylic ester or corticoid 17-carboxylic ester 21-carbonic ester I as claimed

in claim 1, wherein R(1), A, Y, Z, R(3) and R(4) are defined as in claim 1, and wherein R(2) is linear or branched (C_1-C_8)-alkyl,  or .

3. A process for preparing a compound I as claimed in claim 1, wherein

a) a compound of the formula II



II,

in which R(5) is OH and the remaining substituents have the abovementioned meanings,

a1) is reacted with an activated carboxylic acid of the formula III, preferably a halide or anhydride or azolide,

$$R(6)\text{-}CO\text{-}(O)_n\text{-}[(C_1\text{-}C_4)\text{-alkyl}]_m\text{-}R(1) \qquad \text{III}$$

in which:

n is zero,

m is zero or 1, and

$[(C_1-C_4)$-alkyl] and R(1) have the abovementioned meanings, and

R(6) is Cl, Br, $O[\text{-}CO\text{-}(O)_n\text{-}[(C_1\text{-}C_4)\text{-alkyl}]_m\text{-}R(1)]_1$-, $-O\text{-}C(O)\text{-}CF_3$, or another activated acid radical, or

a2) is reacted with a haloformate of the formula III,

in which
n is 1,
m is zero or 1,
[(C_1-C_4)-alkyl] and R(1) have the abovementioned meanings and R(6) is Cl, Br or I, or

a3) is reacted with a carboxylic acid of the formula III itself, in which
R(6) is OH, and
n is zero,
and the other substituents are given in formula III,

in the presence of water-eliminating reagents (DCCI, etc.),

or wherein

b) compounds of the formula II



II,

in which R(5) is Br, I, or a sulfonic aryl ester group or sulfonic alkyl ester group, and the other substituents have the meaning given in formula I, are reacted with a salt, preferably a K or Na salt or a trialkylammonium salt, of a carboxylic acid of the formula III,

$$R(6)\text{-}CO\text{-}(O)_n\text{-}[(C_1\text{-}C_4)\text{-alkyl}]_m\text{-}R(1) \qquad III$$

in which
R(6) is -[O⁻Me⁺], and
n is zero,
and the other substituents have the meanings given in formula III,
Me preferably being the cation of an alkali metal salt or of a trialkylammonium salt.

4. A pharmaceutical for treating dermatoses, in particular those which are inflammatory and allergic, which has an effective content of a compound I as claimed in claim 1.

5. A process for treating dermatoses, wherein an effective quantity of a compound I as claimed in claim 1, combined with pharmaceutically customary additives, is applied to the affected skin site.

6. Use of a compound I as claimed in claim 1 for preparing a pharmaceutical for treating dermatoses.